Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

- RaniPill HC achieved 4/4 successful drug delivery of orally administered Humira (adalimumab) -

- RaniPill HC has achieved a cumulative >90% success rate across multiple preclinical studies –

- RaniPill HC shortlisted as a finalist by Fierce Life Sciences Innovation Awards –

SAN JOSE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the successful oral delivery of a monoclonal antibody, Humira (adalimumab), via its high-capacity capsule, the RaniPill HC, in a preclinical study.

“The preclinical results we are sharing today show the potential of the RaniPill platform to orally deliver large molecules, such as antibodies, at high volume, which could enable the replacement of many injectable drugs with an oral pill,” said Mir Hashim, PhD, Chief Scientific Officer for Rani Therapeutics. “The high-capacity version, the RaniPill HC, is capable of delivering up to a 500%-plus higher drug payload than Rani’s existing oral biologics capsule and has achieved a cumulative >90% success rate for delivery across multiple preclinical studies. The data generated to date with the RaniPill HC give us confidence as we progress the high-capacity device towards clinical readiness.”

Data Highlights

Rani conducted a preclinical study tracking the serum concentrations of adalimumab, following the oral administration of the enteric-coated, RaniPill HC capsule containing 11mg of Humira (adalimumab) to four canine models. The RaniPill HC successfully delivered adalimumab in all of the subjects. All device remnants were excreted normally without sequelae.

Rani has orally administered the RaniPill HC in multiple preclinical studies, including with teriparatide and adalimumab, and has achieved a greater than 90% drug delivery success rate across such studies.

Fierce Life Sciences Innovation Awards 2023

Rani Therapeutics has been shortlisted as a finalist in the 2023 Fierce Life Sciences Innovation Awards in the ”Drug Delivery Technology” category. Winners will be announced on November 29, 2023.

The shortlist recognizes the RaniPill HC, Rani Therapeutics’ high-capacity, drug-agnostic capsule designed to enable oral delivery of biologic medicines that are otherwise only available as injections. Rani’s mission is to alleviate the burden of painful injections for patients suffering from chronic diseases.